New hope for Tough-to-Treat lung cancer: experimental drug takes on chemo in major trial
NCT ID NCT06927986
Summary
This study is testing whether a new drug called SYS6010 works better and is safer than standard platinum-based chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) that has stopped responding to previous targeted therapies. It will involve about 380 adults whose cancer has progressed after treatment with EGFR inhibitor drugs. The main goal is to see if SYS6010 can keep the cancer from growing for longer than chemotherapy can.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.